Today, December 15, 2025, is the first day of Corona Remedies’ first public offering (IPO) on Indian stock exchanges. Grey market patterns point to a successful listing performance.
Live Corona Remedies Share Price: Efficiency of cash flow
The company’s operating cash flow to EBITDA ratio in FY2025 was 77.46%, as stated in the red herring prospectus (RHP), indicating good cash conversion efficiency.
Live Corona Remedies Share Price: Prior to listing, Corona Remedies’ pre-open price was Rs 1452.
Live Corona Remedies Share Price: India’s prospects for economic expansion
According to the red herring prospectus (RHP), India’s GDP grew by 7% in FY2023, surpassing both advanced and emerging economies. Global supply chain realignment, growing consumption, and favorable demographics are projected to sustain the growth trend.
Live Corona Remedies Share Price: Worldwide trends in healthcare spending
According to the red herring prospectus (RHP), worldwide healthcare spending was approximately 10% of GDP in 2022, whereas India’s healthcare spending was 3.3% of GDP, underscoring the substantial development potential of the Indian healthcare market.
Corona Remedies Share Price Live: In important nations, pharmaceuticals account for 10–20% of healthcare expenditures.
According to the RHP, retail pharmaceuticals made for about one-sixth of healthcare spending in OECD nations in 2021, with pharmaceutical spending in India accounting for 21% of healthcare spending in 2020.
The Indian domestic formulation market is expected to expand at a compound annual growth rate (CAGR) of 8–9% till FY 2030.
According to the RHP, an increase in chronic illnesses and better access to healthcare will help the Indian domestic formulation market, which was estimated to be worth Rs 2.3 trillion in FY 2025, grow to Rs 3.3–3.5 trillion by FY 2030.
Corona Remedies Share Price Live: Details of the selling offer
The whole structure of the Rs 655.68 crore public offering was an offer for sale (OFS) of 0.62 crore shares. Promoters Dr. Kirtikumar Laxmidas Mehta, Minaxi Kirtikumar Mehta, Brinda Ankur Mehta, and Dipabahen Niravkumar Mehta are selling off a portion of their shares under the OFS.
Additionally, investors Anchor Partners, Sepia Investments, and Sage Investment Trust are selling their shares.
The business stated in its red herring prospectus that it anticipates the listing of the equity shares will increase brand awareness, give current owners liquidity, and establish a public market for its shares in India.
Live Corona Remedies Share Price: Prior to listing, Corona Remedies’ pre-open price was Rs 1125.
Live Corona Remedies Share Price: Prior to listing, the company’s pre-open price was Rs 1,062.
Prior to its stock market debut, Corona Remedies Ltd. (CORONA | 544644 | INE02ZQ01018) is holding its pre-open session. The indicative price is now at Rs 1,062.00. With a 0.00% change in both quantity and price, no movement has been noted thus far. As investors position themselves ahead of the IPO filing, the pre-open session’s indicative amount of 6,133 shares reflects early market interest.
As the company gets ready to begin trading, this pre-open price offers a first glimpse of investor emotion and anticipated demand.
What is the most recent grey market premium for Corona Remedies shares?
According to Investorgain.com, Corona Remedies’ IPO final GMP is Rs 342.5, as of December 15, 2025, at 07:57 AM. The projected listing price for Corona Remedies IPO is Rs 1404.5 (cap price + today’s GMP), with a price band of 1062.00. 32.25% is the anticipated percentage gain or loss per share.
